HOWL.US Werewolf Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.9803 USD
Close of Nov 15, 2026
0.2700 1.20
Market cap
USD 47.6M
P/E
-
P/B
2.92x
ROE
-389.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HOWL.US undervalued?

Graham number

The Graham number of Werewolf Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Werewolf Therapeutics Inc fundamental analysis

No fundamental analysis for Werewolf Therapeutics Inc yet.

Werewolf Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Werewolf Therapeutics Inc

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a…

Full company profile